Vera Moulton Wall Center

Clinical Research

Access to Clinical Trials of Investigational Drugs

Stanford has participated in several major clinical trials of new therapies for pulmonary hypertension. These new therapies include subcutaneous prostacyclin (UT15 or Remodulin), oral endothelin antagonists (Bosentan or Tracleer and sitaxsetan) as well as other novel drug therapies developed at Stanford. Our clinical research nurses, Val Scott RN, MSN has extensive experience in clinical nursing, including ICU and CCU experience, and over 10 years experience in both industry and NIH sponsored clinical trials. For additional information about current and upcoming clinical trials please contact Val Scott at (650)725-8082 or please visit the schools's Clinical Trials Directory for information on current Adult Pulmonary Hypertension Trials and Pediatric Pulmonary Hypertension Trials.

Current Clinical Trials

Therapy Title
Bosentan (Tracleer) Effect of Endothelin Receptor A & B Antagonism on Insulin Resistance and Outcomes in Patients with Pulmonary Arterial Hypertension
The Expression of Mts1 in Adults with Pulmonary Arterial Hypertension Preliminary studies have identified that the protein Mts1 may be involved in the development of pulmonary arterial hypertension (PAH). We are currently investigating whether Mts1 can be used as a marker for severity and cause of disease in patients with PAH.

Pending Clinical Trials

Therapy Title
Rituximab A Randomized, Double-blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Severe Systemic Sclerosis-Associated PAH.
Cicletanine A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension

Completed Clinical Trials

Therapy FDA Status Title
Ambrisentan (BSF 208075) Pending FDA approval Evaluating Exercise Capacity in Patients with PAH
Remodulin (UT-15) FDA approved Phase III Randomized Study of UT-15 in PPH Patients
Bosentan FDA approved Multi-Center, Randomized, Double-Blind Study of Bosentan in PH Patients
Bosentan FDA approved Long Term Open-Label Study in PH Patients who Participated in Controlled Clinical Studies of Bosentan
Bosentan FDA approved Multi-Center Open-Label Single-Arm Safety Study of Bosentan in PH Patients
Oral UT 15 FDA approved A 16-week International Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Safety and Efficacy of Oral UT-15C Sustained Release Tablets in Combination with ETRA and/or PDE51 in Patients with PAH


Footer Links: